Try our Advanced Search for more refined results
Health
-
March 20, 2026
Eye On ERISA: A Chat With King & Spalding's Darren Shuler
Increased scrutiny of health plans and the high costs of care are fueling a litigation uptick that's coming not just from plan participants but also from employers frustrated with their third-party administrators, said Darren Shuler, a partner at King & Spalding LLP. Here, Shuler speaks with Law360 about litigation trends involving the Employee Retirement Income Security Act.
-
March 20, 2026
Prestige Picks Up Breathe Right In $1.05B Deal
Consumer healthcare company Prestige Consumer Healthcare Inc. revealed on Friday that it has agreed to acquire a portfolio of brands including Breathe Right nasal strips from Foundation Consumer Healthcare, advised by Skadden Arps Slate Meagher & Flom LLP, in a $1.05 billion deal.
-
March 19, 2026
4th Circ. Leery Of W.Va. Opioid Towns' Abatement Arguments
During a heated hourlong oral argument Thursday, two Fourth Circuit judges interrogated an attorney for West Virginia municipalities stricken by the opioid crisis about whether the public nuisance of overly available drugs had already been abated, leaving only redress of resulting harms.
-
March 19, 2026
HHS Can't Block Trans Care Under Kennedy Edict, Court Says
A coalition of 21 states and the District of Columbia prevailed on Thursday in their challenge to a Trump administration move to cut access to gender-affirming care for minors when an Oregon federal judge agreed to void a policy statement from Health and Human Services Secretary Robert F. Kennedy Jr.
-
March 19, 2026
Pharma Group Can't Halt Colo. Law Over Drug Discount Rules
A Colorado federal judge denied a bid by the Pharmaceutical Research and Manufacturers of America seeking to halt enforcement of a state law guarding providers' ability to contract with pharmacies to distribute discounted drugs under the federal 340B program.
-
March 19, 2026
Legislative Update: Cannabis And Psychedelics Bill Roundup
Virginia lawmakers last week gave final approval to legislation that would tax and regulate the sale of adult-use cannabis, Georgia legislators passed a dramatic expansion of the state's medical cannabis program, and Iowa lawmakers approved a bill to designate kratom as a Schedule I substance. Here are the major moves in cannabis and psychedelics legislation from the past week.
-
March 19, 2026
11th Circ. Partially Reopens Aetna Twin Birth Coverage Fight
The Eleventh Circuit on Thursday undid Aetna's escape from a worker's coverage dispute over an extended hospital stay for her newborn twins, agreeing with the lower court that allegations failed to state a claim for violating federal benefits law but holding that an amended complaint should have been allowed.
-
March 19, 2026
Drug Co. Can't Claim Most Docs Contain Trade Secrets At Trial
A Manhattan federal judge ruled Thursday that a pharmaceutical consulting company won't be allowed to argue to a jury that thousands of documents it did not enter into evidence contain trade secrets amid an ongoing misappropriation trial.
-
March 19, 2026
$30K Wage Settlement Too Vague To Approve, Judge Says
An Ohio federal judge rejected a proposed $30,000 settlement to a wage and hour suit against a group of home care staffing agencies Thursday, saying the settlement paperwork isn't clear enough to determine whether the deal is fair.
-
March 19, 2026
Calif. Families Sue Rady Health Over Move To End Trans Care
Four families have asked a state judge to prevent California's largest pediatric health system from cutting off gender-affirming care for minors, alleging the move would violate state antidiscrimination laws and leave them scrambling to find new providers, some more than 100 miles away.
-
March 19, 2026
Maya Kowalski Says Atty Made Her 'Uncomfortable'
The attorney who persuaded a jury to award $261 million to Netflix documentary subject Maya Kowalski also provided unsolicited dating and sex advice to his 18-year-old client and arranged an advance funding loan for the Kowalski family in violation of Florida Bar rules, according to a statement Kowalski filed.
-
March 19, 2026
Fla. Court Won't Pause Restoration Of Medicaid Benefits
A Florida federal court has declined to pause an injunction ordering the state to restore family Medicaid to more than a million low-income enrollees, but extended deadlines to reinstate benefits and to send adequate termination notices.
-
March 19, 2026
Goodwin, S&C Steer Up To $785M Sale Of ADHD Drug
Goodwin Procter LLP-advised Collegium Pharmaceutical Inc. unveiled plans Thursday to acquire attention deficit hyperactivity disorder drug Azstarys from Sullivan & Cromwell LLP-led Corium Therapeutics Holdings LLC for up to $785 million.
-
March 19, 2026
TriZetto Wants To Expand IP Claims Against Infosys
Cognizant TriZetto Software Group has asked a Texas federal judge to allow it to amend its trade secret suit against Infosys Ltd., saying a recent discovery has revealed that Infosys' alleged misconduct "goes much deeper."
-
March 19, 2026
Detroit Clinic Zones Impede Free Speech, Protesters Say
Anti-abortion advocates sued the city of Detroit, claiming an ordinance creating speech-restriction zones around healthcare facilities unlawfully blocks peaceful counseling outside an abortion clinic on the city's west side.
-
March 19, 2026
CVS, Caremark Pocket Money Meant For Rebates, Suit Claims
CVS charges drug manufacturers "exorbitant" fees in exchange for pushing their products, then pockets the money instead of funneling it toward customer rebates as it promises, a federal lawsuit alleges, accusing the company of collecting billions of dollars at customers' expense and violating the anti-racketeering statute.
-
March 19, 2026
Ohio Home Health Co. Settles OT Suit For $975K
A Columbus-area home health services company will pay $975,000 to end a lawsuit accusing it of misclassifying its program managers as exempt from overtime, according to an Ohio federal court filing.
-
March 19, 2026
Zynex Gets OK For Ch. 11 Plan Reducing Debt By $50M
Zynex Inc., a pain management medical device maker, received confirmation Thursday of its Chapter 11 plan, which reduces its debt by about $50 million and turns over the company to its creditors.
-
March 18, 2026
Key Details As 3rd Circ. Ponders FCA's Fate, $1.6B J&J Fine
Third Circuit judges Wednesday explored divergent views of the False Claims Act's constitutionality and a record fraud verdict against Johnson & Johnson, expressing little eagerness to gut the FCA's whistleblower mechanism, and voicing uncertainty about evidence and jury instructions underpinning the drug promotion punishment.
-
March 18, 2026
Zuckerberg, Snap CEO Likely Must Testify In School MDL Trial
A California federal judge indicated Wednesday that Meta and Snap's CEOs will likely need to testify in an upcoming school district bellwether trial in the social media addiction multidistrict litigation, and declined Meta's bid to block arbitration demands, saying, "Meta's got plenty of money, go file a motion with the arbitration panel."
-
March 18, 2026
Stryker Hit With Another Suit After Cyberattack
Another proposed class action has been filed against Michigan-based medical technology company Stryker Corp. in the wake of a March 11 cyberattack on the company that was reportedly perpetrated by hackers tied to Iran.
-
March 18, 2026
SelectQuote Looks To Escape Investors' Kickback Probe Suit
SelectQuote has asked a New York federal judge to dismiss a proposed class action accusing it of harming investors by concealing a kickback scheme, which is currently the subject of a suit by the U.S. Department of Justice, arguing the existence of the government's suit is not enough to show the shareholders were damaged.
-
March 18, 2026
UnitedHealth Customers Denied Class Cert. In PrEP Suit
Two UnitedHealthcare customers can't turn their Affordable Care Act lawsuit against a company subsidiary into a class action, a Minnesota federal judge ruled Wednesday, denying the pair's bid to represent thousands of customers in litigation accusing the subsidiary of failing to approve full coverage for PrEP.
-
March 18, 2026
Ed. Dept. Flouting Mental Health Funding Order, States Claim
The U.S. Department of Education is flouting orders that it fund K-12 mental health grants given to public schools by only partially funding the grants and threatening to withhold remaining funds, a group of state attorneys general told a Washington federal court.
-
March 18, 2026
Texas Panel Says Doc Can't Block Report Of Suspension
A Texas appellate court ruled Wednesday that a San Antonio physician can't stop his suspension from being reported to national and state health regulators, finding that he failed to show the hospital acted with specific intent to cause harm as is required to overcome statutory peer‑review immunity.
Expert Analysis
-
Class Actions At The Circuit Courts: March Lessons
In this month's review of class action appeals, Mitchell Engel at Shook Hardy discusses four recent rulings from January and identifies practice tips from cases involving allegations of violations of consumer fraud regulations, the Fair Credit Reporting Act, employment law and breach of contract statutes.
-
FDA's Biosimilarity Guidance Holds Uncertain Implications
The U.S. Food and Drug Administration's new draft guidance aimed at simplifying the biosimilarity demonstration process may not be enough to overcome the barriers that have historically constrained biosimilar competition, and could affect biosimilar access in unexpected ways, say analysts at Analysis Group.
-
Unpacking Key Themes From NY's New Healthcare Strategy
New York Gov. Kathy Hochul's 2026 State of the State agenda, read together with the state's fiscal year 2027 executive budget, reflect a clear framework to utilize Medicaid as the state's operating platform for healthcare reform, say attorneys at Sheppard.
-
5 Different AI Systems Raise Distinct Privilege Issues
A New York federal court’s recent U.S. v. Heppner decision, holding that a defendant’s use of Claude was not privileged, only addressed one narrow artificial intelligence system, but lawyers must recognize that the spectrum of AI tools raises different confidentiality and privilege questions, says Heidi Nadel at HP.
-
Health Co.'s 'Success Story' Misstep Holds HIPAA Lessons
Cadia Healthcare Facilities' fall settlement with the U.S. Department of Health and Human Services for improperly disclosing patients' protected health information in online success stories is an instructive example of Health Insurance Portability and Accountability Act risks that can arise from digital marketing efforts, say attorneys at Woods Rogers.
-
Opinion
AI-Assisted Arbitration Needs Safeguards To Ensure Fairness
As tribunals and arbitral institutions increasingly use artificial intelligence tools in their decision-making processes, clear disclosure standards and procedural safeguards are necessary to ensure that efficiency gains do not erode the fairness principles on which arbitration depends, says Alexander Lima at Wesco International.
-
Trans Care Enforcement Landscape Is Evolving Quickly
The recent coordinated federal effort to reshape pediatric gender-affirming care through enforcement and funding pressure has created a rapidly evolving regulatory environment marked by shifting risk assessments and potential downstream market effects for healthcare institutions and life sciences companies, say attorneys at Arnall Golden.
-
Series
Playing Piano Makes Me A Better Lawyer
Playing piano and practicing law share many parallels relating to managing complexity: Just as hearing an entire musical passage in my head allows me to reliably deliver the message, thinking about the audience's impression helps me create a legal narrative that keeps the reader engaged, says Michael Shepherd at Fish & Richardson.
-
11th Circ. May Bring Tectonic Shift To FCA Qui Tam Actions
The Eleventh Circuit's upcoming decision in Zafirov v. Florida Medical Associates, assessing whether the False Claims Act permits ordinary citizens to stand as officers of the federal government, could significantly limit private relators' ability to bring FCA actions, say attorneys at Saul Ewing.
-
AI-Generated Doc Ruling Guides Attys On Privilege Risks
A New York federal court's ruling, in U.S. v. Heppner, that documents created by a defendant using an artificial intelligence tool were not privileged, can serve as a guide to attorneys for retaining attorney-client or work-product privilege over client documents created with AI, say attorneys at Sher Tremonte.
-
To Survive FCA Actions, Small Cos. Must Take Offensive Steps
A fumbled response to False Claims Act allegations can doom lower-middle-market businesses, and with FCA enforcement hitting record levels for two years, smaller companies must have offensive strategies ready that focus their limited resources on defeating civil qui tam and federal criminal actions, says Derrelle Janey at Olshan Frome.
-
The Law Firm Merger Diaries: Leadership Strategy After Day 1
For law firm leaders, ensuring a newly combined law firm lives up to its promise, both in its first days of operation and well after, includes tough decisions, clear and specific communication, and cheerleading, says Peter Michaud at Ballard Spahr.
-
How US Liability Law Is Becoming The Primary Regulator Of AI
Comprehensive federal AI regulation remains fragmented and uncertain — but U.S. courts, applying long-standing doctrines of liability and responsibility, are actively shaping how AI systems are designed, deployed and governed, and companies are aligning their AI practices because courts may hold them accountable if they do not, says Alexander Lima at Wesco International.
-
Record FCA Recoveries Signal Intensified Healthcare Focus
In its recently released False Claims Act statistics, the U.S. government's emphasis on record healthcare recoveries and government-initiated healthcare matters last year indicates robust enforcement ahead, though the administration's focus on current policy objectives also extends beyond the healthcare sector, say attorneys at Epstein Becker.
-
Fed. Circ. In Jan.: On The Validity Of Expert Testimony
The Federal Circuit's recent decision in Barry v. DePuy, addressing whether expert testimony is admissible even if it does not strictly adhere to the court's claim construction, suggests that exclusion via a Daubert motion is appropriate only when the line to improper testimony is clearly crossed, say attorneys at Knobbe Martens.